DALLAS, July 16, 2009 (GLOBE NEWSWIRE) -- BeaconEquity.com announces an investment report featuring antiviral/anti-cancer drug maker Peregrine Pharmaceuticals Inc. (PPHM). The report includes financial and investment analysis, and pertinent industry information you need to know to make an educated investment decision.
The investment report on Peregrine Pharmaceuticals Inc. (Nasdaq:PPHM) should be of particular interest to other biopharmaceutical/biotechnology companies: Amgen Inc. (Nasdaq:AMGN), Schering-Plough Corp. (NYSE:SGP), Genzyme Corp. (Nasdaq:GENZ) and Gilead Sciences Inc. (Nasdaq:GILD).
It is available at: http://beaconequity.com/i/PPHM/
Get our alerts BEFORE the rest of the market. Follow us on Twitter: http://twitter.com/BeaconEquity
Peregrine Pharmaceuticals Inc. is a biopharmaceutical engaged in the development of clinical-stage antibodies for the treatment of the hepatitis C infection and various forms of cancer. It has a portfolio of two clinical-stage candidate drugs, including bavituximab for the treatment of tumors and HCV infection.
Read and post on Twitter and top Stock Message Boards for these stocks and more, all in real-time: http://www.BoardCentral.com/
In the report, the analyst notes:
"In its 10-Q report dated March 12, 2009, the Company intends to pursue more private and government contracts as a source of working capital through its subsidiary, Avid. The Company states it must raise at least $7.5 million from either a new stock issuance or the sale of Avid.
"The Company announced on July 1 that it had been awarded a European patent for its In-line labeling technology, which was developed for the production of anti-cancer antibodies. The July issue of The Journal of Nuclear Medicine said a recent published study demonstrated that In-Line labeling reduces cost and complexity in the production of radiolabeled cancer drugs."
To read the entire report visit: http://beaconequity.com/i/PPHM/
BeaconEquity.com is one of the industry's largest small-cap report providers. Beacon strives to provide a balanced view of many promising small-cap companies that would otherwise fall under the radar of the typical Wall Street investor. We provide investors with an excellent first step in their research and due diligence by providing daily trading ideas, and consolidating the public information available on them. For more information on Beacon Research, please visit http://www.BeaconEquity.com
Beacon Equity Disclosure
DO NOT BASE ANY INVESTMENT DECISION UPON ANY MATERIALS FOUND ON THIS REPORT. We are not registered as a securities broker-dealer or an investment adviser either with the U.S. Securities and Exchange Commission (the "SEC") or with any state securities regulatory authority. We are neither licensed nor qualified to provide investment advice. BeaconEquity Research nor its affiliates have a beneficial interest in the mentioned company; nor have they received compensation of any kind for any of the companies listed in this communication. The information contained in our report is not an offer to buy or sell securities. We distribute opinions, comments and information free of charge exclusively to individuals who wish to receive them.